Overt Hepatic Encephalopathy clinical trials

Explore recruiting overt hepatic encephalopathy clinical trials.

Recruiting overt hepatic encephalopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overt Hepatic Encephalopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

Belgium, Spain, France, Germany, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Norfloxacin for amelioration of portal hypertension in decompensated cirrhosis - a randomized, placebo-controlled, double-blinded clinical trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Controlled, Open Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy

Germany, Belgium, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Spain, Hungary, Netherlands, Belgium, Bulgaria, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Denmark, Belgium, Spain, Netherlands, Germany, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Hungary, Netherlands, Spain, Germany, Belgium, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Overt Hepatic Encephalopathy trials by city

Overt Hepatic Encephalopathy in Toronto Overt Hepatic Encephalopathy in Vancouver Overt Hepatic Encephalopathy in Montreal Overt Hepatic Encephalopathy in Calgary Overt Hepatic Encephalopathy in Edmonton Overt Hepatic Encephalopathy in Ottawa Overt Hepatic Encephalopathy in Winnipeg Overt Hepatic Encephalopathy in Quebec City Overt Hepatic Encephalopathy in Hamilton Overt Hepatic Encephalopathy in Kitchener Overt Hepatic Encephalopathy in London Overt Hepatic Encephalopathy in Halifax Overt Hepatic Encephalopathy in New York Overt Hepatic Encephalopathy in Los Angeles Overt Hepatic Encephalopathy in Chicago Overt Hepatic Encephalopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease